<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of hirsutism in premenopausal women</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of hirsutism in premenopausal women</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of hirsutism in premenopausal women</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Chang, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William F Crowley, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hirsutism, defined as excessive growth of terminal hair in a female, is common (affects between 5 and 10 percent of females of reproductive age) and is associated with significant emotional distress and depression [<a href="#rid1">1-3</a>]. It is usually an indication of an underlying endocrine disorder (most commonly polycystic ovary syndrome [PCOS])  (<a class="graphic graphic_table graphicRef65205" href="/z/d/graphic/65205.html" rel="external">table 1</a>) [<a href="#rid4">4-7</a>].</p><p>Hirsutism is a clinical diagnosis defined by the presence of excess terminal hair growth (dark, coarse hairs) in androgen-dependent areas (eg, upper lip, chin, midsternum, upper abdomen, back, and buttocks) [<a href="#rid4">4,8</a>]. There are several conditions characterized by generalized or "excess" hair growth that do <strong>not</strong> represent hirsutism and do not require biochemical evaluation with serum androgens, including hypertrichosis and "unwanted hair" (any hair growth [usually light, unpigmented facial hair] that the patient finds bothersome). This type of hair is not a sign of androgen excess, and it does not respond to androgen suppression therapies.</p><p>The treatment of hirsutism in women with the two most common causes of hirsutism (PCOS and nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency [NCCAH]) will be reviewed here. The pathogenesis, causes, and evaluation of hirsutism, and the removal of unwanted hair are discussed separately. Direct methods of hair removal are reviewed briefly here and in greater detail elsewhere. Other uncommon disorders that cause hirsutism such as classic congenital adrenal hyperplasia (CAH), androgen-secreting tumors, and ovarian hyperthecosis are associated with more severe hyperandrogenism and are also reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7439.html" rel="external">"Pathophysiology and causes of hirsutism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7441.html" rel="external">"Evaluation of premenopausal women with hirsutism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1589.html" rel="external">"Removal of unwanted hair"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13917.html" rel="external">"Evaluation and management of postmenopausal hyperandrogenism"</a>.)</p><p></p><p class="headingAnchor" id="H4223844490"><span class="h1">INITIAL VISIT</span></p><p class="headingAnchor" id="H3882190872"><span class="h2">What is the patient's underlying diagnosis?</span><span class="headingEndMark"> — </span>The first step before starting therapy in hirsute females is to establish or confirm the underlying diagnosis (see  <a class="medical medical_review" href="/z/d/html/7441.html" rel="external">"Evaluation of premenopausal women with hirsutism"</a>). Most females (80 to 85 percent) have polycystic ovary syndrome (PCOS), defined by the presence of two of the following three criteria (oligomenorrhea, hyperandrogenism, and polycystic ovaries on pelvic ultrasound) (see  <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">"Diagnosis of polycystic ovary syndrome in adults", section on 'Diagnosis'</a>). The two main pharmacologic options for hirsutism (combined estrogen-progestin oral contraceptives [COCs] and antiandrogens) can only be used in females not seeking fertility.</p><p>A much lower percentage of females with hirsutism have nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (NCCAH). Their clinical presentation is very similar and often indistinguishable from PCOS. Although NCCAH is an adrenal disorder, the management of hirsutism is largely the same as for females with PCOS. (See  <a class="medical medical_review" href="/z/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/147.html" rel="external">"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p class="headingAnchor" id="H2446269111"><span class="h2">Baseline Ferriman-Gallwey score</span><span class="headingEndMark"> — </span>We use the modified scale of Ferriman and Gallwey (F-G) to grade the severity of hair growth objectively. We perform an assessment at baseline and at follow-up visits. We do not use these scores to identify candidates for pharmacologic treatment, but we do use them to monitor response to therapy.</p><p>Nine androgen-sensitive sites are graded from 0 to 4  (<a class="graphic graphic_figure graphicRef66629" href="/z/d/graphic/66629.html" rel="external">figure 1</a>) [<a href="#rid9">9</a>]. The criteria for identifying hirsutism using the F-G score are variable because the expression of hair growth varies considerably among racial/ethnic groups. Based on population studies, an F-G score &gt;8 is considered abnormal for Black or White females. For Mediterranean, Hispanic, and Middle Eastern females, an F-G score ≥9 to 10 is considered abnormal, and for Asian females, a score of ≥2 qualifies.</p><p>There are a number of limitations of the F-G score including lack of clinician familiarity with its use, patient use of cosmetic hair removal methods (shaving, plucking, waxing) before the initial evaluation and while receiving therapy, and the variable scores based on ethnicity. This issue is reviewed in more detail separately. </p><p class="headingAnchor" id="H4201564449"><span class="h2">Assess degree of emotional distress</span><span class="headingEndMark"> — </span>Regardless of the baseline F-G score, the impact of the hirsutism on the patient's quality of life should be assessed [<a href="#rid1">1-3</a>]. Females with scores below those that are considered to be abnormal can experience significant distress from the presence of excess terminal hair, particularly on the face and neck  (<a class="graphic graphic_figure graphicRef66629" href="/z/d/graphic/66629.html" rel="external">figure 1</a>). We therefore treat any female with "patient-important" hirsutism, defined in the Endocrine Society guidelines as "unwanted sexual hair growth of any degree that causes sufficient distress for females to seek additional treatment" [<a href="#rid10">10</a>]. If not done previously, screening for depression should be performed. (See <a class="local">'Management'</a> below and  <a class="medical medical_review" href="/z/d/html/7441.html" rel="external">"Evaluation of premenopausal women with hirsutism", section on 'Emotional distress/depression'</a> and  <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">"Diagnosis of polycystic ovary syndrome in adults", section on 'Depression and anxiety disorders'</a>.)</p><p class="headingAnchor" id="H2381966844"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3755911449"><span class="h2">Review strategies and expectations</span><span class="headingEndMark"> — </span>We review the available pharmacologic options and methods of direct hair removal (photoepilation [laser and intense pulsed light] and electrolysis).</p><p class="bulletIndent1"><span class="glyph">●</span>For all pharmacologic therapies for hirsutism, we suggest a trial of at least six months before making any changes in dose, adding a medication, or switching to a new medication [<a href="#rid10">10</a>]. (See <a class="local">'Six-month assessment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our approach is similar to that outlined in the 2018 Endocrine Society clinical guidelines [<a href="#rid10">10</a>]. We suggest that most females with hirsutism start with pharmacologic therapy, and we consider combined estrogen-progestin oral contraceptives (COCs) to be the first-line drug  (<a class="graphic graphic_algorithm graphicRef142573" href="/z/d/graphic/142573.html" rel="external">algorithm 1</a>). Exceptions would include females with contraindications to COC use or those who choose not to take COCs. (See <a class="local">'Combined estrogen-progestin oral contraceptives'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An antiandrogen (<a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>) is then added if the clinical response is suboptimal after six months of therapy  (<a class="graphic graphic_algorithm graphicRef142573" href="/z/d/graphic/142573.html" rel="external">algorithm 1</a>) [<a href="#rid10">10</a>]. We try to avoid antiandrogen monotherapy unless the patient has adequate contraception (such as an intrauterine device [IUD]), because of the potential risk that a developing male fetus could be undervirilized. (See <a class="local">'Antiandrogens'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do not typically start with combination therapy (both a COC and an antiandrogen) as initial treatment. However, in occasional patients with severe hirsutism causing significant distress or in females who have not had a good response to COC monotherapy in the past, it is reasonable to initiate combination therapy with a COC and antiandrogen [<a href="#rid10">10</a>]. (See <a class="local">'Combined with COCs'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reasonable expectations should be discussed; females should be counseled that drug therapy is unlikely to completely eliminate already existing hair growth, but that hair may become less coarse, grow more slowly, and/or require less frequent use of cosmetic methods (shaving, plucking, waxing).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For females with overweight or obesity, we also recommend lifestyle interventions with a goal of weight loss, in addition to the specific therapy they choose for hirsutism. Weight loss results in improved insulin sensitivity, a decrease in serum androgens, and, in some cases, a return of ovulatory cycles (see <a class="local">'Obesity'</a> below). The impact on hirsutism is less clear. The majority of females with hirsutism have polycystic ovary syndrome (PCOS). Additional metabolic evaluation for them is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">"Diagnosis of polycystic ovary syndrome in adults", section on 'Cardiometabolic risk assessment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insulin-lowering agents are not an effective therapy for hirsutism, and we do not suggest their use [<a href="#rid9">9,11</a>]. (See <a class="local">'Treatments not routinely recommended'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Direct methods of hair removal such as photoepilation (laser and intense pulsed light), are also referred to as "permanent" hair reduction techniques. Females may choose to start these options at any point; some choose this as their initial therapy. However, hyperandrogenic females are likely to experience hair regrowth because of the continued stimulation of hair follicles by endogenous androgens. Females who decide to pursue laser/intense pulsed light should also be on pharmacologic therapy to suppress androgens and prevent new hair growth. (See <a class="local">'Role of direct hair removal methods'</a> below.)</p><p></p><p class="headingAnchor" id="H4062878940"><span class="h2">Combined estrogen-progestin oral contraceptives</span><span class="headingEndMark"> — </span>For most females, COCs are our first-line drug; an antiandrogen can then be added if the clinical response is suboptimal after six months of therapy  (<a class="graphic graphic_algorithm graphicRef142573" href="/z/d/graphic/142573.html" rel="external">algorithm 1</a>). Females should be aware that COCs and antiandrogens do not have US Food and Drug Administration (FDA) approval for the indication of hirsutism. Therefore, these therapies represent "off-label" use. These preparations also provide additional non-hirsutism benefits such as contraception, cycle management, and reduction of other hyperandrogenic symptoms such as acne. It is assumed that transdermal and vaginal estrogen-progestin contraceptive preparations are also effective for hirsutism, but data are limited.</p><p>Clinical trial data on the impact of COCs on hirsutism have been somewhat limited. However, in a network meta-analysis that included trials of COC therapy, the pool-weighted mean difference in Ferriman-Gallwey (F-G) score versus placebo was -7.20 (95% CI -11.96 to -2.52) [<a href="#rid11">11</a>]. Although there is no established minimally important difference established for the F-G score, virtually all females would consider these reductions to be clinically important [<a href="#rid10">10</a>]. COCs are also effective for the treatment of acne that often accompanies hirsutism, especially in females with PCOS. These data are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/129467.html" rel="external">"Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Oral contraceptives'</a>.)</p><p>For females with PCOS, COCs provide the additional benefit of preventing the development of endometrial hyperplasia and restoring regular menstrual cyclicity. The treatment of PCOS, including the use of COCs for hirsutism, is reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults"</a>.)</p><p class="headingAnchor" id="H3650681133"><span class="h3">Mechanisms of action in hyperandrogenism/hirsutism</span><span class="headingEndMark"> — </span>The contraceptive mechanisms of COC action are well known and are discussed separately. COC therapy reduces hyperandrogenism and hirsutism by the following mechanisms (see  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Noncontraceptive uses'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhibition of gonadotropin secretion</strong> – Inhibition of ovarian androgen production through suppression of luteinizing hormone (LH) secretion. COC therapy decreases LH and, to a lesser extent, follicle-stimulating hormone (FSH) secretion in hyperandrogenic females [<a href="#rid12">12-15</a>]. In studies of gonadotropin secretion in females with PCOS, serum FSH concentrations fell more rapidly than did serum LH concentrations, but the fall in serum LH was greater (70 versus 50 percent) [<a href="#rid12">12,13</a>]. The result was decreased ovarian secretion of testosterone and other androgens by the ovaries.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased SHBG</strong> – Stimulation of the hepatic production of sex hormone-binding globulin (SHBG), thereby increasing androgen binding in serum and reducing serum free androgen concentrations. In the circulation, testosterone (and estradiol) are bound with high affinity to SHBG and, with lesser affinity but greater extent, to albumin. In females, only approximately 1.0 to 1.5 percent of the testosterone in serum is in the physiologically active free form [<a href="#rid16">16,17</a>]. Androgens and insulin both decrease the hepatic production of SHBG. Since both are often increased in hyperandrogenic females, these females have lower serum SHBG concentrations than normal [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/z/d/html/7442.html" rel="external">"Steroid hormone metabolism in polycystic ovary syndrome", section on 'Control of androgen production'</a> and  <a class="medical medical_review" href="/z/d/html/7442.html" rel="external">"Steroid hormone metabolism in polycystic ovary syndrome", section on 'Role of insulin'</a>.)</p><p></p><p class="bulletIndent1">Estrogen (and COCs) causes a dose-dependent increase in serum SHBG concentrations over three to four weeks in hyperandrogenic females [<a href="#rid15">15,20,21</a>]. As serum SHBG concentrations increase, serum free testosterone concentration decreases. This increase is smaller in females treated with a COC containing a progestin that has significant androgenic properties (eg, <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a>) [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1">When hormonally evaluating females who have been on a COC, it is best to discontinue the medications for at least 8, if not 12, weeks as it takes at least this length of time for measured androgens and SHBG levels to return to basal values [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduction in serum total and free testosterone concentrations</strong> – As a result of both inhibition of LH secretion and increase in SHBG production, serum free testosterone concentrations decrease by approximately 50 percent in hyperandrogenic females treated with a COC  (<a class="graphic graphic_figure graphicRef61395" href="/z/d/graphic/61395.html" rel="external">figure 2</a>) [<a href="#rid12">12-14,24,25</a>]. Serum total testosterone concentrations also fall, but not as much as free testosterone, because of the increase in serum SHBG concentrations. (See  <a class="medical medical_review" href="/z/d/html/7442.html" rel="external">"Steroid hormone metabolism in polycystic ovary syndrome", section on 'Control of androgen production'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary mechanisms</strong> – COCs may also ameliorate hyperandrogenism by decreasing adrenal androgen secretion [<a href="#rid26">26-29</a>], inhibiting the peripheral conversion of testosterone to dihydrotestosterone (DHT), and inhibiting the binding of DHT to androgen receptors. However, the evidence that COCs have any of these actions is not strong, and it is unlikely that these mechanisms contribute importantly to their benefit in hyperandrogenic females.</p><p></p><p class="headingAnchor" id="H1630271239"><span class="h3">Choice of pill</span><span class="headingEndMark"> — </span>Although data suggest that COCs have similar efficacy for hirsutism [<a href="#rid10">10,11</a>], we typically choose one that contains a progestin with low or neutral androgenicity, such as <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> or norgestimate  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 2</a> and <a class="graphic graphic_algorithm graphicRef142573" href="/z/d/graphic/142573.html" rel="external">algorithm 1</a>). Some clinicians prefer to start with a COC containing an antiandrogenic progestin, <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a>, or <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a> (CPA). Drospirenone is structurally related to <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>, and it is a very weak antiandrogen at the dose employed in many contraceptives (3 mg). [<a href="#rid30">30</a>]. Data comparing COCs containing drospirenone or CPA with COCs containing other progestins are limited but do not suggest a clinically important advantage for hirsutism [<a href="#rid10">10,11,31-33</a>]. In addition, there have been concerns about a possible excess risk of venous thromboembolism (VTE) with both of these newer progestins compared with other progestins such as norethindrone and <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a>. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'</a>.)</p><p>We typically avoid COC preparations containing the most androgenic progestin, <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a>. Although limited clinical trial data suggest that levonorgestrel-containing COCs have similar benefits for hirsutism as other less androgenic COCs [<a href="#rid10">10,11,34</a>], they may have adverse metabolic effects. In one study, a COC containing desogestrel, a third-generation progestin with low androgenicity, had more favorable effects on lipid profiles when compared with a COC containing levonorgestrel [<a href="#rid10">10,35</a>], a potential concern in females with PCOS who have metabolic concerns at baseline. (See  <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults", section on 'Metabolic effects of COCs in PCOS'</a>.)</p><p>COCs containing desogestrel or gestodene are sometimes used. While they are among the least androgenic progestins, there have been concerns about a higher risk of venous thromboembolism  (<a class="graphic graphic_table graphicRef121107" href="/z/d/graphic/121107.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Venous thromboembolism'</a>.) </p><p>We start most patients on a COC formulation that contains 20 mcg of ethinyl estradiol, particularly females with obesity or over age 39 (risk factors for VTE). However, some clinicians may start with 30 to 35 mcg if the hirsutism is more significant and the patient has no VTE risk factors. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'</a>.)</p><p>There had been concerns that the COCs with lower doses of ethinyl estradiol (20 mcg) would be less effective for ovarian androgen suppression. However, in a meta-analysis of 42 studies, suppression of serum total and free testosterone concentrations was similar with 20 mcg versus 30 to 35 mcg dose pills [<a href="#rid36">36</a>]. The transdermal contraceptive patch and vaginal ring suppress serum androgens to a similar degree; limited data suggest that they are beneficial for hirsutism, but their impact on hirsutism has not been studied [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">"Contraception: Transdermal contraceptive patches"</a> and  <a class="medical medical_review" href="/z/d/html/16682.html" rel="external">"Contraception: Hormonal contraceptive vaginal rings"</a>.)</p><p class="headingAnchor" id="H83727907"><span class="h3">Six-month assessment</span><span class="headingEndMark"> — </span>We suggest a trial of at least six months before making any changes in dose, adding a medication, or switching to a new medication. This is because the growth phase of a hair follicle is approximately six months; a significant reduction in hair growth may not occur before then.</p><p>In addition, we do try to obtain an F-G score at baseline and at each follow-up visit  (<a class="graphic graphic_figure graphicRef66629" href="/z/d/graphic/66629.html" rel="external">figure 1</a>). Although we make therapeutic changes primarily based upon the patient's assessment of her response to therapy, the F-G score may help to confirm a good response or suboptimal response  (<a class="graphic graphic_algorithm graphicRef142573" href="/z/d/graphic/142573.html" rel="external">algorithm 1</a>).</p><p>We do not suggest routine monitoring of serum androgens to assess the response to drug therapy. However, if there is progression of hirsutism during therapy, repeat biochemical evaluation is warranted. (See  <a class="medical medical_review" href="/z/d/html/7441.html" rel="external">"Evaluation of premenopausal women with hirsutism"</a>.)</p><p class="headingAnchor" id="H524686868"><span class="h4">Clinical improvement</span><span class="headingEndMark"> — </span>For females who are satisfied with the degree of improvement in their hirsutism after six months of COC therapy, we suggest continuing the COC based upon the patient's priorities (stop if she decides to pursue fertility). (See <a class="local">'Duration of drug therapy'</a> below.)</p><p class="headingAnchor" id="H823472607"><span class="h4">Suboptimal response: Add antiandrogen</span><span class="headingEndMark"> — </span>If the patient is not satisfied with the degree of improvement in her hirsutism after six months of monotherapy with a COC, we suggest adding an antiandrogen  (<a class="graphic graphic_algorithm graphicRef142573" href="/z/d/graphic/142573.html" rel="external">algorithm 1</a>) [<a href="#rid10">10,38</a>].</p><p class="headingAnchor" id="H2273583496"><span class="h2">Antiandrogens</span></p><p class="headingAnchor" id="H292868304"><span class="h3">Combined with COCs</span><span class="headingEndMark"> — </span>As noted above, we most commonly <strong>add</strong> an antiandrogen to a COC when the initial response to six months of COC monotherapy has been inadequate. Monitoring of females on combination COC-antiandrogen therapy is the same as that described for COC monotherapy  (<a class="graphic graphic_algorithm graphicRef142573" href="/z/d/graphic/142573.html" rel="external">algorithm 1</a>). (See <a class="local">'Six-month assessment'</a> above.)</p><p>We suggest against combination therapy as the initial therapy for most females. However, in occasional patients with severe hirsutism causing significant distress or in females who have not had a good response to COC monotherapy in the past, it is reasonable to initiate combination therapy with a COC and antiandrogen [<a href="#rid10">10,38</a>].</p><p class="headingAnchor" id="H1125353341"><span class="h3">Monotherapy</span><span class="headingEndMark"> — </span>Although antiandrogens appear to be as effective as COCs for hirsutism [<a href="#rid39">39</a>], we suggest not using them as <strong>monotherapy</strong>, because of the potential adverse effects on a developing male fetus in utero. However, in females who cannot conceive or who are using a reliable contraceptive method, either a COC <strong>or</strong> an antiandrogen can be used as initial therapy as they appear to have similar efficacy  (<a class="graphic graphic_algorithm graphicRef142573" href="/z/d/graphic/142573.html" rel="external">algorithm 1</a>) [<a href="#rid10">10</a>].</p><p>Antiandrogen therapy is also effective for those with acne in addition to hirsutism [<a href="#rid40">40,41</a>].</p><p>The approach for females with contraindications to COC use are reviewed below. (See <a class="local">'Females with contraindications to COCs'</a> below.)</p><p class="headingAnchor" id="H2484336311"><span class="h3">Available antiandrogens: Efficacy</span><span class="headingEndMark"> — </span>In a network meta-analysis of pharmacologic therapies for hirsutism [<a href="#rid11">11</a>], analyses of seven trials of individual antiandrogens versus placebo (two <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> trials 100 mg/day; three <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> 2.5 to 5 mg/day; two <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">flutamide</a> 500 mg/day), each antiandrogen showed a significant reduction in hirsutism scores. The effects of the three drugs were similar. Of note, we suggest not using flutamide because of its potential hepatotoxicity. When results of the seven trials of the three antiandrogens were pooled, antiandrogens were significantly more effective than placebo at reducing F-G scores, with a pooled weighted mean difference of -7.02 (95% CI -11.51 to -2.52).</p><p>Available antiandrogens that are commonly used for hirsutism include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spironolactone</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">Spironolactone</a>, our first choice of antiandrogen, is an aldosterone and androgen receptor antagonist that is structurally similar to progestin. It competes with DHT for binding to the androgen receptor and inhibits enzymes involved in androgen biosynthesis. (See <a class="local">'Suggested drug: spironolactone'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Finasteride</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">Finasteride</a> inhibits 5-alpha-reductase type 2, the enzyme that converts testosterone to DHT. Only a partial inhibitory effect occurs when used for excess hair growth because the enhanced 5-alpha-reductase activity in hirsutism involves both the type 1 and type 2 enzymes. It is used by some clinicians at doses of 1 to 5 mg/day, but there are particular concerns about its inadvertent use in early pregnancy, given the essential role of DHT in the development of male external genitalia. <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">Dutasteride</a>, an inhibitor of both 5-alpha-reductase types 1 and 2, would theoretically be a more effective therapy than finasteride for hirsutism. It is used for the treatment of benign prostatic hyperplasia, but we suggest against its use for females with hirsutism as there is a substantial risk of preventing the development of normal male external genitalia during early pregnancy [<a href="#rid10">10</a>]. In addition, there are no clinical trial data demonstrating its efficacy for hirsutism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flutamide</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">Flutamide</a> is a nonsteroidal androgen receptor antagonist. It is used primarily in the management of prostate cancer, but it has been used off-label for managing hirsutism. The efficacy of flutamide (250 to 750 mg/day) is similar to that of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> (100 to 200 mg/day) and <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> (5 mg/day) [<a href="#rid42">42-46</a>]. However, we suggest against the use of flutamide for hirsutism since it has been associated with hepatotoxicity [<a href="#rid47">47-49</a>], even at doses as low as 62.5 mg (a dose that has not been shown to be effective for hirsutism in randomized clinical trials) [<a href="#rid10">10,50</a>]. While some studies have reported that low-dose flutamide (≤250 mg) is not hepatotoxic [<a href="#rid51">51-54</a>], others have identified adverse hepatic effects:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 10-year surveillance study of 203 females receiving <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">flutamide</a> (62.5 to 125 mg/day), 22 (11 percent) experienced elevated serum concentrations of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a retrospective study of 414 females taking <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">flutamide</a> (125 to 250 mg/day) alone or with COCs, 6 percent stopped therapy in the first year due to elevated transaminases [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a series of seven females with acne or hirsutism who developed hepatoxicity while taking <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">flutamide</a> (150 to 250 mg/day), five required urgent liver transplantation (four of the five survived) [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other </strong>–<strong> </strong>Two weak antiandrogens, CPA (a 17-hydroxyprogesterone derivative) and <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a>, are the progestin component in some COCs:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">Drospirenone</a>, a progestin used in some COCs, is a very weak antiandrogen. The dose used with ethinyl estradiol in COCs (3 mg) is equivalent to approximately 25 mg of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> [<a href="#rid10">10</a>]. Drospirenone-containing COCs have been associated with a higher risk of VTE than COCs containing second-generation progestins. A progestin-only contraceptive pill containing drospirenone is available, but no data are available for its possible efficacy for treating hirsutism. (See <a class="local">'Choice of pill'</a> above and  <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)", section on 'Formulations'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CPA competes with DHT for binding to the androgen receptor and reduces serum LH and ovarian androgen concentrations. It is used in a low dose (2 mg) as the progestin component of COCs, or as a higher dose (12.5 to 100 mg) as monotherapy or with estrogen. It is available in almost all countries but the United States. Drug regulatory agencies in Europe have recommended limiting its use to "second-line" therapy because of a perceived increase in risk of hepatotoxicity compared with other available progestins [<a href="#rid56">56,57</a>].</p><p></p><p class="headingAnchor" id="H979048601"><span class="h3">Suggested drug: spironolactone</span><span class="headingEndMark"> — </span>There are few comparative studies of different antiandrogens in females with hirsutism. Since they all appear to be effective for hirsutism, the choice of drug depends upon its availability, cost, side effects, and potential toxicity  (<a class="graphic graphic_algorithm graphicRef142573" href="/z/d/graphic/142573.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>We suggest <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>, as clinical trials have shown consistent benefit, and it is considered to be safe [<a href="#rid10">10,58,59</a>]. We start with 50 mg twice daily and increase to 100 mg twice daily as needed. The side effects of spironolactone include hyperkalemia (a rare problem in females with normal renal function and aldosterone secretion). However, we measure a serum potassium level in all patients after one month of spironolactone administration. Females with renal insufficiency should not be prescribed spironolactone, because of the high risk of hyperkalemia.</p><p></p><p class="bulletIndent1">Other side effects include gastrointestinal discomfort and irregular menstrual bleeding. In females taking <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> (200 mg daily) who develop irregular uterine bleeding, decreasing the spironolactone dose to 100 mg daily may reduce or resolve the bleeding. As noted above, we suggest against spironolactone monotherapy because of the potential risk that a developing male fetus could be undervirilized. An exception is that females with an IUD or subdermal progestin implant can use an antiandrogen monotherapy because they are at a low risk of unintended pregnancy.</p><p></p><p class="headingAnchor" id="H2084095680"><span class="h2">Duration of drug therapy</span><span class="headingEndMark"> — </span>Pharmacologic therapy is usually continued during the reproductive years as the underlying condition typically persists during this window, and hirsutism recurs when treatment is discontinued [<a href="#rid60">60,61</a>].</p><p>When pregnancy is desired, all pharmacologic treatments for hirsutism must be discontinued. Antiandrogens, in particular, are contraindicated in females trying to conceive because of potential adverse effects on male sexual development.</p><p class="headingAnchor" id="H4194241682"><span class="h2">Role of direct hair removal methods</span><span class="headingEndMark"> — </span>Direct or mechanical methods of hair removal, including electrolysis and photoepilation (laser and intense pulsed light), are also referred to as "permanent" hair reduction techniques. However, females with underlying hyperandrogenemia are likely to experience hair regrowth because of the continued stimulation of hair follicles by endogenous androgens. This can be prevented by suppressing endogenous androgens with pharmacologic therapy.</p><p>Melanin pigment is necessary for photoepilation; therefore, hair that is naturally white or blonde is not amenable to treatment. We therefore suggest electrolysis for these patients. Patients with tanned or darkly pigmented skin are at higher risk for unintended thermal injury to the epidermis during photoepilation. Other adverse effects that occur more commonly in females with dark skin include inflammation, blistering, hyperpigmentation, hypopigmentation, and/or rarely, scarring [<a href="#rid62">62</a>]. In females with fair skin, the risk of side effects other than temporary perifollicular inflammation is low.</p><p>Direct methods of hair removal, including laser and intense pulsed light, are reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1589.html" rel="external">"Removal of unwanted hair", section on 'Laser and intense pulsed light'</a>.)</p><p class="headingAnchor" id="H3895520357"><span class="h2">Topical therapy</span><span class="headingEndMark"> — </span>Females who desire a more rapid response to laser therapy can add eflornithine cream. Vaniqa (eflornithine hydrochloride cream 13.9%) is a topical drug that is available for the treatment of unwanted facial hair in females. It is an inhibitor of hair growth, not a depilatory, and it must be used indefinitely to prevent regrowth [<a href="#rid63">63,64</a>]. In two clinical trials of combined eflornithine and laser therapy, a more rapid response was observed when compared with laser treatments alone [<a href="#rid65">65,66</a>]. Use of this drug is limited by its high cost.</p><p class="headingAnchor" id="H3126952879"><span class="h1">TREATMENTS NOT ROUTINELY RECOMMENDED</span></p><p class="headingAnchor" id="H1415504520"><span class="h2">Metformin</span><span class="headingEndMark"> — </span>Insulin-lowering drugs, which have been used for a number of indications, do not appear to be effective for hirsutism. <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> is used primarily for blood glucose control in patients with type 2 diabetes but has also been used for some indications in females with polycystic ovary syndrome (PCOS). However, it is no longer suggested for treating hirsutism [<a href="#rid10">10</a>].</p><p>We agree with the 2018 Endocrine Society guidelines and suggest against its routine use for hirsutism as <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> has minimal or no benefit [<a href="#rid9">9-11,67</a>].</p><p class="headingAnchor" id="H3787988615"><span class="h2">GnRH agonist or antagonist therapy</span><span class="headingEndMark"> — </span>We suggest against the routine use of gonadotropin-releasing hormone (GnRH) analog therapy (agonist or antagonist) for hirsutism. However, GnRH agonists are sometimes considered for females with severe hyperandrogenemia, menstrual disturbances, and signs of virilization in addition to hirsutism (for example, ovarian hyperthecosis). It should only rarely be used in females with PCOS [<a href="#rid68">68-72</a>]. (See  <a class="medical medical_review" href="/z/d/html/7397.html" rel="external">"Ovarian hyperthecosis", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/13917.html" rel="external">"Evaluation and management of postmenopausal hyperandrogenism", section on 'Ovarian hyperthecosis'</a>.)</p><p>The role of "add-back" estrogen and progestin therapy to prevent bone loss and hot flashes is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7416.html" rel="external">"Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists", section on 'GnRH with add-back therapy'</a>.)</p><p class="headingAnchor" id="H2557888389"><span class="h2">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multidrug therapy</strong> – European investigators have studied the following combinations for the treatment of hirsutism:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A combined estrogen-progestin oral contraceptive (COC) plus <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> and low-dose <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">flutamide</a> [<a href="#rid51">51-53</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> plus <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">flutamide</a> [<a href="#rid54">54,73</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>A COC plus <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> in adolescents and females with hirsutism and oligomenorrhea [<a href="#rid74">74</a>]</p><p></p><p class="bulletIndent1">The combinations in these trials were effective in the treatment of hirsutism. In addition, <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">flutamide</a> reduced the accumulation of visceral fat, and <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> improved insulin sensitivity.</p><p></p><p class="bulletIndent1">In the absence of additional clinical trial data for these regimens, we suggest against their routine use. In addition, as noted above, we do not recommend treating hirsutism with <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">flutamide</a>, because of potential hepatotoxicity and because there are other effective and safer antiandrogens. (See <a class="local">'Suggested drug: spironolactone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical antiandrogens</strong> – Limited data suggest that topical canrenone (the active metabolite of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>) and <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> provide little or no benefit for hirsutism [<a href="#rid75">75,76</a>]. Thus, we suggest against their use. One topical antiandrogen, <a class="drug drug_general" data-topicid="129396" href="/z/d/drug information/129396.html" rel="external">clascoterone</a>, has been approved for the treatment of acne, but it has not yet been studied for hirsutism [<a href="#rid77">77</a>].</p><p></p><p class="headingAnchor" id="H732734318"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H2680068479"><span class="h2">Females with NCCAH</span><span class="headingEndMark"> — </span>Given their relative lack of benefit for hirsutism and their potential side effects, we suggest against glucocorticoid therapy for the routine treatment of hirsutism. Like other females with hirsutism, we suggest combined estrogen-progestin oral contraceptives (COCs) as first-line therapy. An exception is in females with nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (NCCAH) who do not respond to or cannot tolerate COC and antiandrogen therapies [<a href="#rid10">10</a>]. Glucocorticoids are also indicated for ovulation induction in females with NCCAH. (See  <a class="medical medical_review" href="/z/d/html/147.html" rel="external">"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Women'</a>.)</p><p>Exogenous glucocorticoids are used long term to manage hirsutism and maintain ovulatory cycles in females with classic CYP21A2 deficiency but have also been used to treat hirsutism in females with the nonclassic form of CYP21A2 deficiency (NCCAH). In two trials of glucocorticoid therapy in females with NCCAH (one randomized, one nonrandomized), glucocorticoids were more effective than COCs or antiandrogens for suppressing serum adrenal androgen concentrations (dehydroepiandrosterone [DHEA] and dehydroepiandrosterone sulfate [DHEAS]) but less effective for decreasing hirsutism scores [<a href="#rid78">78,79</a>]. (See  <a class="medical medical_review" href="/z/d/html/147.html" rel="external">"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p class="headingAnchor" id="H3707502537"><span class="h2">Obesity</span><span class="headingEndMark"> — </span>For hirsute females with obesity, including those with polycystic ovary syndrome (PCOS), we recommend lifestyle changes<strong> </strong>in addition to starting pharmacologic therapy. We avoid COCs in females who are obese and over age 40 years because of an excess risk of venous thromboembolism (VTE) and other cardiovascular complications. A list of relative and absolute contraindications to COCs is found separately. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Eligibility criteria (WHO and CDC)'</a>.)</p><p class="headingAnchor" id="H3592642974"><span class="h2">Coexisting depression</span><span class="headingEndMark"> — </span>Depression and anxiety symptoms are common in females with hirsutism, but the optimal management of the mood disorder is unclear. It is important to monitor the patient's mood symptoms during treatment. If they do not improve (or worsen), the patient should be referred for further evaluation and treatment. Some studies suggest that treatment of the hirsutism can improve quality of life and reduce depression and anxiety symptoms [<a href="#rid1">1,80</a>]. (See  <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Postmenopausal females</span><span class="headingEndMark"> — </span>In postmenopausal females with new hirsutism that is severe or rapidly progressive, the possibility of an androgen-secreting tumor or ovarian hyperthecosis must be excluded before initiating treatment. If there is no evidence of a tumor, treatment options include antiandrogens or direct hair removal. In menopausal females with ovarian stromal hyperthecosis and severe hirsutism, bilateral oophorectomy may be considered. (See  <a class="medical medical_review" href="/z/d/html/13917.html" rel="external">"Evaluation and management of postmenopausal hyperandrogenism"</a> and  <a class="medical medical_review" href="/z/d/html/7397.html" rel="external">"Ovarian hyperthecosis"</a>.)</p><p class="headingAnchor" id="H324943332"><span class="h2">Females with contraindications to COCs</span><span class="headingEndMark"> — </span>For females with contraindications to COC use, antiandrogens may be given as initial therapy, as long as the individual is using some form of reliable contraception. For example, in a female with a thrombophilia who cannot take an estrogen-containing contraceptive, an approach to management of hirsutism could include a long-acting reversible contraceptive such as a levonorgestrel-releasing IUD and an antiandrogen such as <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>. (See  <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'</a>.)</p><p class="headingAnchor" id="H1958979761"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110097.html" rel="external">"Society guideline links: Polycystic ovary syndrome"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110632.html" rel="external">"Society guideline links: Hirsutism"</a>.)</p><p class="headingAnchor" id="H10404951"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15608.html" rel="external">"Patient education: Hirsutism (excess hair growth in women) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2170.html" rel="external">"Patient education: Hirsutism (excess hair growth in females) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition </strong>–<strong> </strong>Hirsutism, defined as excessive male-pattern hair growth in a female, is common (affects between 5 and 10 percent of females of reproductive age) and is associated with significant emotional distress and depression. It is usually an indication of an underlying endocrine disorder (most commonly polycystic ovary syndrome [PCOS])  (<a class="graphic graphic_table graphicRef65205" href="/z/d/graphic/65205.html" rel="external">table 1</a>). (See <a class="local">'Initial visit'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates for treatment </strong>–<strong> </strong>We consider any female with patient-important hirsutism to be a candidate for treatment (pharmacologic, direct hair removal, or both). (See <a class="local">'Baseline Ferriman-Gallwey score'</a> above and <a class="local">'Assess degree of emotional distress'</a> above and <a class="local">'Initial visit'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacotherapy </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>COCs </strong>–<strong> </strong>For the majority of females with hirsutism who choose pharmacologic therapy, we suggest combined estrogen-progestin oral contraceptives (COCs) as initial therapy  (<a class="graphic graphic_algorithm graphicRef142573" href="/z/d/graphic/142573.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). COCs and antiandrogens have similar efficacy, but we prefer COCs because antiandrogen monotherapy has potential adverse effects on a developing male fetus. (See <a class="local">'Combined estrogen-progestin oral contraceptives'</a> above and <a class="local">'Monotherapy'</a> above.)</p><p></p><p class="bulletIndent2">Although we do not suggest one particular COC over another, it is reasonable to avoid preparations with the most androgenic progestin, <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a>, which has less desirable metabolic effects. (See <a class="local">'Combined estrogen-progestin oral contraceptives'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adding an antiandrogen </strong>–<strong> </strong>For females with a suboptimal cosmetic result after six months of COC monotherapy, we typically add an antiandrogen. We suggest <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> as the antiandrogen of choice  (<a class="graphic graphic_algorithm graphicRef142573" href="/z/d/graphic/142573.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Antiandrogens'</a> above.)</p><p></p><p class="bulletIndent2">it is important to wait at least six months before making any changes in dose, adding a medication, or switching to a new medication. This is because the growth phase of a hair follicle is approximately six months; a significant reduction in hair growth may not occur before then. (See <a class="local">'Six-month assessment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Combination COC-antiandrogen therapy </strong>–<strong> </strong>In occasional females with either severe hirsutism or hirsutism causing severe emotional distress, we start with combination therapy (a COC <strong>and</strong> an antiandrogen). However, we do not use combination therapy as a standard approach. (See <a class="local">'Combined with COCs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatments we do not recommend </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We suggest against the use of <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">flutamide</a> for hirsutism because of its potential hepatotoxicity (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Suggested drug: spironolactone'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We suggest not using <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> for hirsutism (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Treatments not routinely recommended'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special populations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For females with nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (NCCAH), we suggest COCs rather than glucocorticoids as initial therapy for hirsutism. (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Females with NCCAH'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For females with hyperandrogenism undergoing direct hair removal methods, we suggest that pharmacologic therapy be added or continued to minimize hair regrowth (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Role of direct hair removal methods'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The approach to other patients, including those with obesity, depression, contraindications to COC use and postmenopausal females with new-onset hirsutism are reviewed above. (See <a class="local">'Special populations'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Clayton WJ, Lipton M, Elford J, et al. A randomized controlled trial of laser treatment among hirsute women with polycystic ovary syndrome. Br J Dermatol 2005; 152:986.</a></li><li><a class="nounderline abstract_t">Lipton MG, Sherr L, Elford J, et al. Women living with facial hair: the psychological and behavioral burden. J Psychosom Res 2006; 61:161.</a></li><li><a class="nounderline abstract_t">Hahn S, Janssen OE, Tan S, et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol 2005; 153:853.</a></li><li><a class="nounderline abstract_t">Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med 2005; 353:2578.</a></li><li><a class="nounderline abstract_t">Souter I, Sanchez LA, Perez M, et al. The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstet Gynecol 2004; 191:1914.</a></li><li><a class="nounderline abstract_t">Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev 2000; 21:363.</a></li><li><a class="nounderline abstract_t">Di Fede G, Mansueto P, Pepe I, et al. High prevalence of polycystic ovary syndrome in women with mild hirsutism and no other significant clinical symptoms. Fertil Steril 2010; 94:194.</a></li><li><a class="nounderline abstract_t">FERRIMAN D, GALLWEY JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21:1440.</a></li><li><a class="nounderline abstract_t">Cosma M, Swiglo BA, Flynn DN, et al. Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008; 93:1135.</a></li><li><a class="nounderline abstract_t">Martin KA, Anderson RR, Chang RJ, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:1233.</a></li><li><a class="nounderline abstract_t">Barrionuevo P, Nabhan M, Altayar O, et al. Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis. J Clin Endocrinol Metab 2018; 103:1258.</a></li><li><a class="nounderline abstract_t">Givens JR, Andersen RN, Wiser WL, Fish SA. Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive. J Clin Endocrinol Metab 1974; 38:727.</a></li><li><a class="nounderline abstract_t">Givens JR, Andersen RN, Wiser WL, et al. The effectiveness of two oral contraceptives in suppressing plasma androstenedione, testosterone, LH, and FSH, and in stimulating plasma testosterone-binding capacity in hirsute women. Am J Obstet Gynecol 1976; 124:333.</a></li><li><a class="nounderline abstract_t">Raj SG, Raj MH, Talbert LM, et al. Normalization of testosterone levels using a low estrogen-containing oral contraceptive in women with polycystic ovary syndrome. Obstet Gynecol 1982; 60:15.</a></li><li><a class="nounderline abstract_t">Dewis P, Petsos P, Newman M, Anderson DC. The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol. Clin Endocrinol (Oxf) 1985; 22:29.</a></li><li><a class="nounderline abstract_t">Vermeulen A, Stoïca T, Verdonck L. The apparent free testosterone concentration, an index of androgenicity. J Clin Endocrinol Metab 1971; 33:759.</a></li><li><a class="nounderline abstract_t">Pardridge WM, Mietus LJ, Frumar AM, et al. Effects of human serum on transport of testosterone and estradiol into rat brain. Am J Physiol 1980; 239:E103.</a></li><li><a class="nounderline abstract_t">Mathur RS, Moody LO, Landgrebe SC, et al. Sex-hormone-binding globulin in clinically hyperandrogenic women: association of plasma concentrations with body weight. Fertil Steril 1982; 38:207.</a></li><li><a class="nounderline abstract_t">Zhang YW, Stern B, Rebar RW. Endocrine comparison of obese menstruating and amenorrheic women. J Clin Endocrinol Metab 1984; 58:1077.</a></li><li><a class="nounderline abstract_t">Easterling WE Jr, Talbert LM, Potter HD. Serum testosterone levels in the polycystic ovary syndrome. Effect of an estrogen-progestin on protein binding of testosterone. Am J Obstet Gynecol 1974; 120:385.</a></li><li><a class="nounderline abstract_t">Cullberg G, Hamberger L, Mattsson LA, et al. Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome. Acta Obstet Gynecol Scand 1985; 64:195.</a></li><li><a class="nounderline abstract_t">Bowles SM, Mills RJ. Sex hormone binding globulin: effect of synthetic steroids on the assay and effect of oral contraceptives. Ann Clin Biochem 1981; 18:226.</a></li><li><a class="nounderline abstract_t">Sánchez LA, Pérez M, Centeno I, et al. Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study. Fertil Steril 2007; 87:712.</a></li><li><a class="nounderline abstract_t">Casey JH. Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. Clin Endocrinol (Oxf) 1975; 4:313.</a></li><li><a class="nounderline abstract_t">Kim MH, Rosenfield RL, Hosseinian AH, Schneir HG. Ovarian hyperandrogenism with normal and abnormal histologic findings of the ovaries. Am J Obstet Gynecol 1979; 134:445.</a></li><li><a class="nounderline abstract_t">Fern M, Rose DP, Fern EB. Effect of oral contraceptives on plasma androgenic steroids and their precursors. Obstet Gynecol 1978; 51:541.</a></li><li><a class="nounderline abstract_t">Wiebe RH, Morris CV. Effect of an oral contraceptive on adrenal and ovarian androgenic steroids. Obstet Gynecol 1984; 63:12.</a></li><li><a class="nounderline abstract_t">Wild RA, Umstot ES, Andersen RN, Givens JR. Adrenal function in hirsutism. II. Effect of an oral contraceptive. J Clin Endocrinol Metab 1982; 54:676.</a></li><li><a class="nounderline abstract_t">Carr BR, Parker CR Jr, Madden JD, et al. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment. J Clin Endocrinol Metab 1979; 49:346.</a></li><li><a class="nounderline abstract_t">Muhn P, Fuhrmann U, Fritzemeier KH, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1995; 761:311.</a></li><li><a class="nounderline abstract_t">Batukan C, Muderris II, Ozcelik B, Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol 2007; 23:38.</a></li><li><a class="nounderline abstract_t">Kriplani A, Periyasamy AJ, Agarwal N, et al. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception 2010; 82:139.</a></li><li><a class="nounderline abstract_t">Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril 2012; 98:1053.</a></li><li><a class="nounderline abstract_t">Breitkopf DM, Rosen MP, Young SL, Nagamani M. Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. Contraception 2003; 67:349.</a></li><li><a class="nounderline abstract_t">Knopp RH, Broyles FE, Cheung M, et al. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception 2001; 63:1.</a></li><li><a class="nounderline abstract_t">Zimmerman Y, Eijkemans MJ, Coelingh Bennink HJ, et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update 2014; 20:76.</a></li><li><a class="nounderline abstract_t">White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. Am J Obstet Gynecol 2005; 192:2055.</a></li><li><a class="nounderline abstract_t">Ezeh U, Huang A, Landay M, Azziz R. Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome. J Womens Health (Larchmt) 2018; 27:892.</a></li><li><a class="nounderline abstract_t">Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf) 2000; 52:587.</a></li><li><a class="nounderline abstract_t">Carmina E, Dreno B, Lucky WA, et al. Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. J Endocr Soc 2022; 6:bvac003.</a></li><li><a class="nounderline abstract_t">Garg V, Choi JK, James WD, Barbieri JS. Long-term use of spironolactone for acne in women: A case series of 403 patients. J Am Acad Dermatol 2021; 84:1348.</a></li><li><a class="nounderline abstract_t">Swiglo BA, Cosma M, Flynn DN, et al. Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008; 93:1153.</a></li><li><a class="nounderline abstract_t">Cusan L, Dupont A, Gomez JL, et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 1994; 61:281.</a></li><li><a class="nounderline abstract_t">Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999; 84:1304.</a></li><li><a class="nounderline abstract_t">Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85:89.</a></li><li><a class="nounderline abstract_t">Müderris II, Bayram F, Güven M. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil Steril 2000; 73:984.</a></li><li><a class="nounderline abstract_t">Wysowski DK, Freiman JP, Tourtelot JB, Horton ML 3rd. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993; 118:860.</a></li><li><a class="nounderline abstract_t">Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996; 155:209.</a></li><li><a class="nounderline abstract_t">Brahm J, Brahm M, Segovia R, et al. Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature. Ann Hepatol 2011; 10:93.</a></li><li><a class="nounderline abstract_t">Bruni V, Peruzzi E, Dei M, et al. Hepatotoxicity with low- and ultralow-dose flutamide: a surveillance study on 203 hyperandrogenic young females. Fertil Steril 2012; 98:1047.</a></li><li><a class="nounderline abstract_t">Ibáñez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004; 89:1592.</a></li><li><a class="nounderline abstract_t">Ibáñez L, De Zegher F. Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab 2003; 88:4720.</a></li><li><a class="nounderline abstract_t">Ibáñez L, De Zegher F. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. Hum Reprod 2004; 19:1725.</a></li><li><a class="nounderline abstract_t">Ibáñez L, Ong K, Ferrer A, et al. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab 2003; 88:2600.</a></li><li><a class="nounderline abstract_t">Paradisi R, Venturoli S. Retrospective observational study on the effects and tolerability of flutamide in a large population of patients with various kinds of hirsutism over a 15-year period. Eur J Endocrinol 2010; 163:139.</a></li><li><a class="nounderline abstract_t">Anonymous. Germany's cyproterone warning. Lancet 1995; 345:979.</a></li><li><a class="nounderline abstract_t">Heinemann LA, Will-Shahab L, van Kesteren P, et al. Safety of cyproterone acetate: report of active surveillance. Pharmacoepidemiol Drug Saf 1997; 6:169.</a></li><li><a class="nounderline abstract_t">Lobo RA, Shoupe D, Serafini P, et al. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril 1985; 43:200.</a></li><li><a class="nounderline abstract_t">Wong IL, Morris RS, Chang L, et al. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995; 80:233.</a></li><li><a class="nounderline abstract_t">Kokaly W, McKenna TJ. Relapse of hirsutism following long-term successful treatment with oestrogen-progestogen combination. Clin Endocrinol (Oxf) 2000; 52:379.</a></li><li><a class="nounderline abstract_t">Koulouri O, Conway GS. Management of hirsutism. BMJ 2009; 338:b847.</a></li><li><a class="nounderline abstract_t">Somani N, Turvy D. Hirsutism: an evidence-based treatment update. Am J Clin Dermatol 2014; 15:247.</a></li><li><a class="nounderline abstract_t">"The Pink Sheet". August 7, 2000; 62:7.</a></li><li><a class="nounderline abstract_t">Wolf JE Jr, Shander D, Huber F, et al. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Int J Dermatol 2007; 46:94.</a></li><li><a class="nounderline abstract_t">Smith SR, Piacquadio DJ, Beger B, Littler C. Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. Dermatol Surg 2006; 32:1237.</a></li><li><a class="nounderline abstract_t">Hamzavi I, Tan E, Shapiro J, Lui H. A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. J Am Acad Dermatol 2007; 57:54.</a></li><li><a class="nounderline abstract_t">Costello M, Shrestha B, Eden J, et al. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007; :CD005552.</a></li><li><a class="nounderline abstract_t">Chang RJ, Laufer LR, Meldrum DR, et al. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab 1983; 56:897.</a></li><li><a class="nounderline abstract_t">Rittmaster RS, Thompson DL. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. J Clin Endocrinol Metab 1990; 70:1096.</a></li><li><a class="nounderline abstract_t">Steingold K, De Ziegler D, Cedars M, et al. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. J Clin Endocrinol Metab 1987; 65:773.</a></li><li><a class="nounderline abstract_t">Andreyko JL, Monroe SE, Jaffe RB. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin). J Clin Endocrinol Metab 1986; 63:854.</a></li><li><a class="nounderline abstract_t">Gelety TJ, Pearlstone AC, Surrey ES. Short-term endocrine response to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women. Fertil Steril 1995; 64:1074.</a></li><li><a class="nounderline abstract_t">Gambineri A, Patton L, Vaccina A, et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 2006; 91:3970.</a></li><li><a class="nounderline abstract_t">Mitkov M, Pehlivanov B, Terzieva D. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2005; 118:209.</a></li><li><a class="nounderline abstract_t">Carmina E, Koyama T, Chang L, et al. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992; 167:1807.</a></li><li><a class="nounderline abstract_t">Gomez F, Ramelet AA, Rüedi B, Mühlemann M. Lack of effect of a spironolactone-containing cream on hair growth in hirsute women. Dermatologica 1987; 174:102.</a></li><li><a class="nounderline abstract_t">Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol 2020; 156:621.</a></li><li><a class="nounderline abstract_t">Spritzer P, Billaud L, Thalabard JC, et al. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J Clin Endocrinol Metab 1990; 70:642.</a></li><li><a class="nounderline abstract_t">Frank-Raue K, Junga G, Raue F, et al. [Therapy of hirsutism in females with adrenal enzyme defects of steroid hormone biosynthesis: comparison of dexamethasone with cyproterone acetate]. Klin Wochenschr 1990; 68:597.</a></li><li><a class="nounderline abstract_t">Pasch L, He SY, Huddleston H, et al. Clinician vs Self-ratings of Hirsutism in Patients With Polycystic Ovarian Syndrome: Associations With Quality of Life and Depression. JAMA Dermatol 2016; 152:783.</a></li></ol></div><div id="topicVersionRevision">Topic 7444 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888157" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A randomized controlled trial of laser treatment among hirsute women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16880018" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Women living with facial hair: the psychological and behavioral burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16322391" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354894" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical practice. Hirsutism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15592272" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The prevalence of androgen excess among patients with minimal unwanted hair growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10950157" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Role of hormones in pilosebaceous unit development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19338993" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : High prevalence of polycystic ovary syndrome in women with mild hirsutism and no other significant clinical symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13892577" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical assessment of body hair growth in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18252787" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29522147" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29522176" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4823918" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1251854" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The effectiveness of two oral contraceptives in suppressing plasma androstenedione, testosterone, LH, and FSH, and in stimulating plasma testosterone-binding capacity in hirsute women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7201126" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Normalization of testosterone levels using a low estrogen-containing oral contraceptive in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3156694" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5125384" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The apparent free testosterone concentration, an index of androgenicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7395986" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effects of human serum on transport of testosterone and estradiol into rat brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7201937" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sex-hormone-binding globulin in clinically hyperandrogenic women: association of plasma concentrations with body weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6427258" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Endocrine comparison of obese menstruating and amenorrheic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4415747" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Serum testosterone levels in the polycystic ovary syndrome. Effect of an estrogen-progestin on protein binding of testosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3160211" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7197136" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sex hormone binding globulin: effect of synthetic steroids on the assay and effect of oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17118366" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/125164" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/572140" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ovarian hyperandrogenism with normal and abnormal histologic findings of the ovaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/148599" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of oral contraceptives on plasma androgenic steroids and their precursors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6228751" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of an oral contraceptive on adrenal and ovarian androgenic steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6277979" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Adrenal function in hirsutism. II. Effect of an oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/224073" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7625729" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17484511" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20654754" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22795636" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742556" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11257242" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24082040" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15970897" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of oral versus transdermal steroidal contraceptives on androgenic markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29878857" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792338" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Spironolactone as a single agent for long-term therapy of hirsute patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35155970" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33434594" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term use of spironolactone for acne in women: A case series of 403 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18252786" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8299783" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199771" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10634370" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10785225" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7683180" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Fatal and nonfatal hepatotoxicity associated with flutamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7490837" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Flutamide hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21301018" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22795685" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hepatotoxicity with low- and ultralow-dose flutamide: a surveillance study on 203 hyperandrogenic young females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15070917" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557446" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229206" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12788862" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20371655" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Retrospective observational study on the effects and tolerability of flutamide in a large population of patients with various kinds of hirsutism over a 15-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Germany's cyproterone warning</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15073785" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Safety of cyproterone acetate: report of active surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3967781" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7829618" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10718837" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Relapse of hirsutism following long-term successful treatment with oestrogen-progestogen combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19329515" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Management of hirsutism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24889738" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hirsutism: an evidence-based treatment update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : "The Pink Sheet"</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17214730" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17034372" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17270315" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17253562" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6403570" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2156885" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3116031" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2943756" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7589655" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Short-term endocrine response to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16868063" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15653205" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1471702" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3556697" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Lack of effect of a spironolactone-containing cream on hair growth in hirsute women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32320027" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2137832" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2142968" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : [Therapy of hirsutism in females with adrenal enzyme defects of steroid hormone biosynthesis: comparison of dexamethasone with cyproterone acetate].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26942548" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Clinician vs Self-ratings of Hirsutism in Patients With Polycystic Ovarian Syndrome: Associations With Quality of Life and Depression.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
